BERONI GROUP LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.96 AUD | -20.80% |
|
-.--% | -.--% |
| 15/03 | Beroni Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Beroni Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 2.2M 1.42M 119M | Sales 2022 | 862K 558K 46.58M | Capitalization | 75.87M 49.13M 4.1B |
|---|---|---|---|---|---|
| Net income 2021 | -2M -1.29M -108M | Net income 2022 | -8M -5.18M -432M | EV / Sales 2021 | 42.4 x |
| Net cash position 2021 | 2.6M 1.68M 140M | Net cash position 2022 | 1.07M 695K 58.03M | EV / Sales 2022 | 86.8 x |
| P/E ratio 2021 |
-35.6
x | P/E ratio 2022 |
-9.37
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -20.80% |
3 years
3.96
3.96
5 years
3.963.96
10 years
1.527.68
| Managers | Title | Age | Since |
|---|---|---|---|
Bo Qing Zhang
CEO | Chief Executive Officer | 55 | 17/16/17 |
Yap Ting Wong
DFI | Director of Finance/CFO | 62 | 30/16/30 |
Chen Chik Ong
BRD | Director/Board Member | 45 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chen Chik Ong
BRD | Director/Board Member | 45 | - |
John Chiplin
BRD | Director/Board Member | 66 | 01/22/01 |
Richard Buchta
BRD | Director/Board Member | 66 | 01/20/01 |
Beroni Group Limited is an Australia-based international biopharmaceutical company. The Company is engaged in the commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. It is engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. Its diversified portfolio is comprised of virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. It operates in Australia, United States, China and Japan. Its products offering include NicoBloc, CII-ArboViroPlex rRT-PCR assay and stem cell cosmetic products, including AGG Skin-Smoothing and Anti-Wrinkle Facial Mask, ODd Skin Repair Essence, ODd Beroni Beauty Facial Mask, and others.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 52.52M | |
| +34.00% | 664B | |
| +29.29% | 567B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.89% | 148B |
- Stock Market
- Equities
- BTG Stock
